Literature DB >> 25696798

Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors.

Chanjuan Shi1, Raul S Gonzalez2, Zhiguo Zhao3, Tatsuki Koyama3, Toby C Cornish4, Kenneth R Hande5, Ronald Walker6, Martin Sandler7, Jordan Berlin5, Eric H Liu8.   

Abstract

OBJECTIVES: We examined Ki-67 heterogeneity within single and between synchronous liver metastases of small intestine neuroendocrine tumors.
METHODS: There were 27 patients (10 men and 17 women) with two or more liver metastases. The Ki-67 index was used to classify the tumors into World Health Organization grade 1, 2, or 3. The association between Ki-67 heterogeneity and tumor size of liver metastases was analyzed. Correlation of tumor grade with patient survival was also evaluated.
RESULTS: Primary tumors from 20 patients were graded, including 17 grade 1 and three grade 2. A total of 188 liver metastases were resected, including 122 (65%) grade 1, 47 (25%) grade 2, and 19 (10%) grade 3. The highest tumor grade was grade 1 in 10 (37%), grade 2 in nine (33%), and grade 3 in eight (30%) patients. Patients with one or more grade 3 liver lesions had a shorter progression-free survival compared with those with grade 1/2 tumors (P < .001). A positive association was found between tumor size and Ki-67 index (P = .04), as well as between tumor size and intratumoral Ki-67 heterogeneity (P < .001).
CONCLUSIONS: Intratumoral and intertumoral Ki-67 heterogeneity is common and positively correlated with tumor size. The presence of one or more grade 3 liver lesions predicts a worse prognosis. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Liver metastasis; Small intestine; Tumor heterogeneity; Well-differentiated neuroendocrine tumor

Mesh:

Substances:

Year:  2015        PMID: 25696798      PMCID: PMC4354931          DOI: 10.1309/AJCPQ55SKOCYFZHN

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  20 in total

1.  Multiple allelic deletions and intratumoral genetic heterogeneity in men1 pancreatic tumors.

Authors:  O Hessman; B Skogseid; G Westin; G Akerström
Journal:  J Clin Endocrinol Metab       Date:  2001-03       Impact factor: 5.958

2.  Incidence of small bowel cancer in the United States and worldwide: geographic, temporal, and racial differences.

Authors:  Tmirah Haselkorn; Alice S Whittemore; David E Lilienfeld
Journal:  Cancer Causes Control       Date:  2005-09       Impact factor: 2.506

3.  Surgical treatment of advanced-stage carcinoid tumors: lessons learned.

Authors:  J Philip Boudreaux; Bradley Putty; Daniel J Frey; Eugene Woltering; Lowell Anthony; Ivonne Daly; Thiagarajan Ramcharan; Jorge Lopera; Wilfrido Castaneda
Journal:  Ann Surg       Date:  2005-06       Impact factor: 12.969

4.  Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors.

Authors:  Anne Couvelard; Lydia Deschamps; Philippe Ravaud; Gabriel Baron; Alain Sauvanet; Olivia Hentic; Nathalie Colnot; Valérie Paradis; Jacques Belghiti; Pierre Bedossa; Philippe Ruszniewski
Journal:  Mod Pathol       Date:  2008-11-07       Impact factor: 7.842

Review 5.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

6.  Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.

Authors:  A Ahmed; G Turner; B King; L Jones; D Culliford; D McCance; J Ardill; B T Johnston; G Poston; M Rees; M Buxton-Thomas; M Caplin; J K Ramage
Journal:  Endocr Relat Cancer       Date:  2009-05-20       Impact factor: 5.678

7.  A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress.

Authors:  Irvin M Modlin; Manish C Champaneria; Anthony K C Chan; Mark Kidd
Journal:  Am J Gastroenterol       Date:  2007-03-27       Impact factor: 10.864

8.  The palliative benefit of aggressive surgical intervention for both hepatic and mesenteric metastases from neuroendocrine tumors.

Authors:  Anthony J Chambers; Janice L Pasieka; Elijah Dixon; Otto Rorstad
Journal:  Surgery       Date:  2008-10       Impact factor: 3.982

9.  A 5-decade analysis of 13,715 carcinoid tumors.

Authors:  Irvin M Modlin; Kevin D Lye; Mark Kidd
Journal:  Cancer       Date:  2003-02-15       Impact factor: 6.860

10.  Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors.

Authors:  Jonathan Strosberg; Aejaz Nasir; Domenico Coppola; Mark Wick; Larry Kvols
Journal:  Hum Pathol       Date:  2009-04-14       Impact factor: 3.466

View more
  21 in total

Review 1.  Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.

Authors:  Mauro Cives; Jonathan Strosberg
Journal:  Curr Treat Options Oncol       Date:  2017-03

Review 2.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

3.  In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous.

Authors:  Mongkon Charoenpitakchai; Eric Liu; Zhiguo Zhao; Tatsuki Koyama; Won Jae Huh; Jordan Berlin; Kenneth Hande; Ronald Walker; Chanjuan Shi
Journal:  Virchows Arch       Date:  2017-02-17       Impact factor: 4.064

4.  Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.

Authors:  Kendall J Keck; Allen Choi; Jessica E Maxwell; Guiying Li; Thomas M O'Dorisio; Patrick Breheny; Andrew M Bellizzi; James R Howe
Journal:  Ann Surg Oncol       Date:  2017-05-30       Impact factor: 5.344

5.  Impact of Peritoneal Metastasis on Survival of Patients With Small Intestinal Neuroendocrine Tumor.

Authors:  Martha Frances Wright; Justin Cates; Raul S Gonzalez; Satya Das; Jordan D Berlin; Chanjuan Shi
Journal:  Am J Surg Pathol       Date:  2019-04       Impact factor: 6.394

Review 6.  Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Andrew M Bellizzi
Journal:  Surg Oncol Clin N Am       Date:  2020-04       Impact factor: 3.495

7.  Mesenteric Tumor Deposits in Midgut Small Intestinal Neuroendocrine Tumors Are a Stronger Indicator Than Lymph Node Metastasis for Liver Metastasis and Poor Prognosis.

Authors:  Cynthia R Fata; Raul S Gonzalez; Eric Liu; Justin M Cates; Chanjuan Shi
Journal:  Am J Surg Pathol       Date:  2017-01       Impact factor: 6.394

Review 8.  The utility of 68Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors.

Authors:  Amit Tirosh; Electron Kebebew
Journal:  Future Oncol       Date:  2017-10-26       Impact factor: 3.404

9.  DAXX Mutation Status of Embolization-Treated Neuroendocrine Tumors Predicts Shorter Time to Hepatic Progression.

Authors:  Etay Ziv; Samuel L Rice; John Filtes; Hooman Yarmohammadi; F Edward Boas; Joseph P Erinjeri; Elena Nadia Petre; Lynn A Brody; Karen T Brown; Anne M Covey; George I Getrajdman; Majid Maybody; Nitya Raj; Constantinos T Sofocleous; Stephen B Solomon; Diane Reidy-Lagunes
Journal:  J Vasc Interv Radiol       Date:  2018-10-19       Impact factor: 3.464

10.  The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications.

Authors:  Marcela S Cavalcanti; Mithat Gönen; David S Klimstra
Journal:  Int J Endocr Oncol       Date:  2016-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.